

























## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AMPHOTERICIN B

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Abelcet only: Failure of conventional amphotericin B therapy unless contraindicated or clinically significant adverse effects are experienced. Ambisome when treating patients with Aspergillus species, Candida species and/or Cryptococcus species infections: Failure of conventional amphotericin B therapy unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AMPYRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ANTI-HISTAMINES

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Allergic rhinitis: Failure to two of the following, unless contraindicated or clinically significant adverse effects are experienced: levocetirizine, desloratadine, fluticasone propionate nasal suspension, flunisolide nasal solution or triamcinolone acetonide nasal inhaler.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ANTI-HISTAMINE COMBINATIONS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Allergic rhinitis: Failure to two of the following, unless contraindicated or clinically significant adverse effects are experienced: levocetirizine, desloratadine, fluticasone propionate nasal suspension, flunisolide nasal solution or triamcinolone acetonide nasal inhaler.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ARANESP

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Anemia due to myelodysplastic syndrome. Myelofibrosis-associated anemia.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of Procrit, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AUBAGIO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AUSTEDO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

TARDIVE DYSKINESIA: Development of tardive dyskinesia is secondary to a centrally acting dopamine receptor blocking agent (neuroleptic) (e.g., first- or second-generation antipsychotics such as chlorpromazine or aripiprazole, antiemetics such as promethazine or metoclopramide, the tri-cyclic antidepressant amoxapine).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

HUNTINGTON'S DISEASE: Prescribed by or in consultation with a neurologist. TARDIVE DYSKINESIA: Prescribed by or in consultation with a psychiatrist or neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

HUNTINGTON'S DISEASE: Failure of tetrabenazine, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AVASTIN

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Glioblastoma: Patient has progressive disease.

#### **Age Restrictions:**

Age 18 or older.

#### **Prescriber Restrictions:**

All cancer indications: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Non-squamous non-small cell lung cancer: Prescribed in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. Metastatic renal cell carcinoma: Prescribed in combination with interferon alfa.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BAXDELA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Current culture and sensitivity report shows isolated pathogen is a gram-positive or gram-negative organism susceptible to delafloxacin.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

14 days.

#### **Other Criteria:**

Failure of one fluoroquinolone, unless all are contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BELEODAQ

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BELSOMRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For patients 65 years of age and older: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Rozerem, Silenor 6 mg/day or less, trazodone or temazepam. For patients under 65 years of age: Failure of zolpidem or zolpidem CR, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BENLYSTA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Previous anaphylaxis to Benlysta, severe active lupus nephritis or severe active central nervous system lupus.

#### **Required Medical Information:**

Documentation of systemic lupus erythematosus positive for anti-nuclear antibody (ANA) and/or anti-double-stranded DNA [anti-dsDNA]).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Currently receiving standard therapy for systemic lupus erythematosus that includes one or more of the following agents, unless all agents are contraindicated: glucocorticoids (e.g., prednisone), antimalarial (e.g., hydroxychloroquine or chloroquine), non-biologic immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BENZTROPINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Parkinsons disease/Parkinsonism: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amantadine, levodopa/carbidopa, entacapone, pramipexole, ropinirole, selegiline.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BLEOMYCIN

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

BOSULIF

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation that the member has Philadelphia chromosome positive disease.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BOTOX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

CHRONIC MIGRAINE HEADACHE: Persistent history of chronic, debilitating migraine headaches with frequent attacks on more than 15 days per month.

#### **Age Restrictions:**

Strabismus or blepharospasm associated with dystonia: 12 years of age or older.

#### **Prescriber Restrictions:**

Chronic migraine headache: Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Chronic migraine headache: Failure of prophylactic treatment with ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: divalproex, topiramate, timolol or propranolol AND Failure of abortive therapy with ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: sumatriptan, rizatriptan, zolmitriptan, naratriptan, almotriptan, frovatriptan, Relpax, ergotamine/caffeine or dihydroergotamine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BRIVIACT

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following generic antiepileptic drugs, unless contraindicated or clinically significant adverse effects are experienced: lamotrigine, topiramate, oxcarbazepine, carbamazepine, phenytoin, valproic acid or divalproex sodium.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BUTABARBITAL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Insomnia: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Rozerem, Silenor 6 mg/day or less, trazodone or temazepam. For use as a daytime sedative: patient is continuing on this medication without adverse effects.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

C1 ESTERASE INHIBITOR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an immunologist, allergist, hematologist or rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of danazol, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CABOMETYX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Non-small cell lung cancer.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Non-small cell lung cancer: Documentation of an RET gene rearrangement.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CALQUENCE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Previously received at least one prior therapy (e.g., rituximab-containing regimen).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CAPRELSA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Non-small cell lung cancer. Non-medullary thyroid cancer.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Medullary Thyroid Cancer: Symptomatic or progressive disease that is unresectable locally advanced or metastatic. Non-medullary thyroid cancer: Diagnosis of one of the following thyroid cancer subtypes: follicular carcinoma, Hurthle cell carcinoma, papillary carcinoma. Non-Small Cell Lung Cancer: Documentation of RET gene rearrangements.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Medullary and Non-medullary Thyroid Cancer: Prescribed by or in consultation with an oncologist or endocrinologist. Non-small cell lung cancer: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Non-Medullary Thyroid Cancer: Failure of lenvatinib or sorafenib, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CARISOPRODOL/ASPIRIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CARISOPRODOL/ASPIRIN/CODEINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CAYSTON

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CERDELGA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Extensive metabolizer (EM) or intermediate metabolizer (IM) taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor AND IMs or poor metabolizer (PM) taking a strong CYP3A inhibitor.

#### **Required Medical Information:**

An FDA-cleared genotyping test has determined that this patient is a CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CEREZYME

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Type 3 Gaucher disease.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of at least one of the following conditions resulting from Gaucher disease: anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CHLORPROPAMIDE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: glimepiride, glipizide or glipizide/metformin combination product.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CHLORZOXAZONE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CHORIONIC GONADOTROPIN

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure. Treatment of obesity.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CINQAIR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Blood eosinophil count of greater than or equal to 400 cells/mcL within the past 3 months.

#### **Age Restrictions:**

18 years of age or older.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an allergist, pulmonologist, or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced. AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CLADRIBINE

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CLOMIPRAMINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Autistic disorder.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one selective serotonin reuptake inhibitor (e.g., fluoxetine, fluvoxamine, sertraline), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

COMETRIQ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

COTELLIC

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients with wild-type BRAF melanoma.

#### **Required Medical Information:**

Lesion is positive for the BRAF V600E or V600K mutation as detected by an FDA-approved test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with Zelboraf.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CRINONE

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Crinone 8%: Failure to Crinone 4%, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CROFELEMER

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Patient is on anti-retroviral therapy and failure or clinically significant adverse effects to loperamide or diphenoxylate/atropine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CYCLOBENZAPRINE HCL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CYTARABINE

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For acute non-lymphocytic leukemia: use in combination with other approved anti-cancer drugs.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DAKLINZA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. For the treatment of hepatitis C virus genotype 2 and 4. Treatment of HCV genotype 4, 5, or 6 in liver transplantation recipients.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 to 24 weeks based on cirrhosis status, genotype, prior treatment, or ribavirin eligibility.

#### **Other Criteria:**

Must be used in combination with Sovaldi. Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Mavyret, Harvoni, Epclusa, Vosevi, and Zepatier for applicable genotypes.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DIPYRIDAMOLE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DISOPYRAMIDE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DOXEPIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ELIDEL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two medium to high potency topical corticosteroids (e.g., amcinonide, fluticasone propionate, triamcinolone acetonide, betamethasone valerate, fluocinolone acetonide, hydrocortisone butyrate, mometasone furoate, desoximetasone, fluocinonide or betamethasone dipropionate), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

EMEND 40 MG

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

Four weeks.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EMFLAZA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Diagnosis of Duchenne muscular dystrophy (DMD) confirmed by one of the following: Genetic testing (e.g., dystrophin deletion or duplication mutation found) OR if genetic studies are negative (i.e., no mutation identified), positive muscle biopsy (e.g., absence of dystrophin protein).

#### **Age Restrictions:**

5 years of age or older.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of prednisone, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ENBREL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Hidradenitis suppurativa.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

PSORIATIC ARTHRITIS, PLAQUE PSORIASIS: Prescribed by or in consultation with a rheumatologist or dermatologist. RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist. HIDRADENITIS SUPPURATIVA: Prescribed by or in consultation with a rheumatologist, dermatologist or gastrointestinal (GI) specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PLAQUE PSORIASIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ENDARI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age 5 or older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of hydroxyurea, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ENTRESTO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Left ventricular ejection fraction less than or equal to 35%.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a cardiologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ENTYVIO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a gastrointestinal (GI) specialist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Humira or Remicade, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EPCLUSA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Treatment of HCV genotype 1, 2, 3, 4, 5, or 6 with decompensated cirrhosis and sofosbuvir or NS5A-based treatment failure.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSA available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 to 24 weeks based on cirrhosis status, genotype, prior treatment, or ribavirin eligibility.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EPOETIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Anemia due to myelodysplastic syndrome. Anemia associated with myelofibrosis. Anemia secondary to combination ribavirin and interferon-alfa therapy in patients infected with hepatitis C virus.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ERGOLOID MESYLATES

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Alzheimer's dementia: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: donepezil, memantine, rivastigmine or galantamine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ERLEADA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Concurrent use of a gonadotropin-releasing hormone (GnRH) analog or past bilateral orchiectomy. Disease is not metastatic.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or urologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ESBRIET

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ESTROGENS(Fyavolv , Mimvey Lo , Minivelle , Femhrt , Vivelle-Dot , Menostar , Premphase , Premarin , Lopreeza , Alora , Amabelz , Prempro , Mimvey , Climara Pro , Combipatch , Angeliq , Elestrin , Climara , Divigel , Duavee , Activella , Estrace , Evamist , estropipate)

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Atrophic Vaginitis and Kraurosis Vulvae: Failure to one of the following, unless contraindicated or clinically significant adverse effects are experienced: Estradiol vaginal tablet, Femring or Premarin vaginal cream.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

EVZIO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Narcan (naloxone nasal spray), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EXONDYS 51

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Duchenne muscular dystrophy with mutation amenable to exon 51 skipping confirmed by genetic testing.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Currently stable on an oral corticosteroid regimen (e.g., prednisone), unless contraindicated or member has experienced clinically significant adverse effects.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EYLEA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an ophthalmologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FARYDAK

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a hematologist or oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two prior regimens, including Velcade and an immunomodulatory agent (e.g., dexamethasone), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FASENRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Blood eosinophil count of greater than or equal to 150 cells/mcL within the past 3 months.

#### **Age Restrictions:**

12 years of age or older.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an allergist, pulmonologist, or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FENTORA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age 18 or greater.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Through the end of the Plan contract year.

#### **Other Criteria:**

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

FERRIPROX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of deferoxamine, Exjade or Jadenu, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FIORICET WITH CODEINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of naproxen and ibuprofen, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FIORINAL WITH CODEINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of naproxen and ibuprofen, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FIRAZYR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

##### **Age Restrictions:**

Age 18 or greater.

##### **Prescriber Restrictions:**

Prescribed by or in consultation with an immunologist, allergist, hematologist or rheumatologist.

##### **Coverage Duration:**

12 months.

##### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

FLECTOR

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Cancer-related neuropathic pain.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

Acute Pain: 4 weeks. Cancer-related neuropathic pain: Through the end of the Plan contract year.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

FLUOROURACIL

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FORTEO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Total duration of therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) has not exceeded 2 years.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of a bisphosphonate (e.g., alendronate) unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GANCICLOVIR

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GATTEX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GILENYA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Baseline QTc interval greater than or equal to 500 msec. Concurrent use of Class Ia or Class III anti-arrhythmic drugs.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GILOTRIF

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Disease is positive for any of the following sensitizing EGFR mutations, as detected by an FDA-approved test, unless request is for second-line therapy in squamous non-small cell lung cancer: exon 19 deletion, exon 21 [L858R] substitution, L861Q, G719X, or S768I mutations.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GLATIRAMER

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GLYBURIDE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: glimepiride, glipizide or glipizide/metformin combination product.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GLYBURIDE/METFORMIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: glimepiride, glipizide or glipizide/metformin combination product.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GOCOVRI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Member is receiving levodopa-based therapy. Medical justification supports inability to use immediate-release amantadine.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of immediate-release amantadine unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GRANIX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



















## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

HYDROXYZINE PAMOATE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Pruritus: Failure of one of the following topical agents, unless contraindicated or clinically significant adverse effects are experienced: betamethasone, hydrocortisone, triamcinolone, fluticasone, clobetasol, fluocinonide or fluocinolone. Anxiety: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: venlafaxine, buspirone, duloxetine or escitalopram. All other FDA approved indications: Patient is continuing on this medication without adverse effects.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ICLUSIG

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Acute Lymphoblastic Leukemia (ALL): Documentation of Philadelphia chromosome positive (Ph+) disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

IDHIFA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Presence of an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test (e.g., Abbott RealTime IDH2 assay).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Disease has relapsed or is refractory following treatment with a first line chemotherapy regimen (e.g., cytarabine, idarubicin, daunorubicin, cladribine, midostaurin, fludarabine).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ILARIS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Acute gouty arthritis.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of current weight.

#### **Age Restrictions:**

Cryopyrin-Associated Periodic Syndromes: 4 years and older. All other covered indications: 2 years and older.

#### **Prescriber Restrictions:**

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a dermatologist, rheumatologist, or gastrointestinal (GI) specialist. ALL OTHER COVERED INDICATIONS: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

IMATINIB

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

IMBRUVICA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

CHRONIC GRAFT-VERSUS-HOST DISEASE: Prescribed by or in consultation with an oncologist, hematologist, or bone marrow transplant specialist. ALL OTHER INDICATIONS: Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

MANTLE CELL LYMPHOMA: Member has received at least one prior therapy (e.g., Rituxan, vincristine, cytarabine, cisplatin, doxorubicin, Treanda). MARGINAL ZONE LYMPHOMA: Member has received at least one prior anti-CD20-based therapy.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

IMIPRAMINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Depression: Failure of one of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INDOMETHACIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of naproxen and sulindac, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INFLECTRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Psoriatic Arthritis/Plaque Psoriasis: Prescribed by or in consultation with a rheumatologist or dermatologist.

Crohn's Disease/Ulcerative Colitis: Prescribed by or in consultation with a gastrointestinal (GI) specialist.

Rheumatoid Arthritis/Ankylosing Spondylitis: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Rheumatoid Arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

Plaque Psoriasis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INGREZZA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Development of tardive dyskinesia is secondary to a centrally acting dopamine receptor blocking agent (neuroleptic) (e.g., first- or second-generation antipsychotics such as chlorpromazine or aripiprazole, antiemetics such as promethazine or metoclopramide, the tri-cyclic antidepressant amoxapine).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a psychiatrist or neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INLYTA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

FOLLICULAR CARCINOMA, HURTHLE CELL CARCINOMA, PAPILLARY CARCINOMA: Disease is iodine refractory and either unresectable or metastatic.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INTERFERON BETA-1A

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INTERFERON BETA-1B

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

INTERMEZZO 1.75 MG

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INTERMEZZO 3.5 MG

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INTUNIV

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Attention Deficit Hyperactivity Disorder: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: dexamethylphenidate, methylphenidate or mixed amphetamine salts.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

JAKAFI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

POLYCYTHEMIA VERA: Failure of hydroxyurea, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

JUBLIA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of terbinafine tablets, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

JUXTAPID

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Repatha 420 mg, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KADCYLA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Kadcyla will be used as a single-agent therapy.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KADIAN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Medical justification as to why patient cannot take an equivalent daily dose of a generically available strength of Kadian.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KALYDECO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients with cystic fibrosis who are homozygous for the F508del mutation.

#### **Required Medical Information:**

Presence of one mutation in the CFTR gene that is responsive to ivacaftor as detected by an FDA-cleared cystic fibrosis mutation test.

#### **Age Restrictions:**

2 years of age or older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KERYDIN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of terbinafine tablets, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KETOROLAC TROMETHAMINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients with active peptic ulcer disease. Advanced renal impairment or at risk for renal failure due to volume depletion. Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk for bleeding. Patient currently receiving aspirin or NSAIDs (Non-steroidal anti-inflammatory drugs). Patient currently receiving Probenecid or pentoxifylline.

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

5 days.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KEVEYIS

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KEVZARA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KEYTRUDA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

CLASSICAL HODGKIN LYMPHOMA, PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA:  
Prescribed by or in consultation with an oncologist or hematologist. ALL OTHER INDICATIONS: Prescribed by  
or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KISQALI(Kisqali , Kisqali Femara Co-Pack )

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Breast cancer in men.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Breast cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and advanced or metastatic.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For Kisqali: Prescribed in combination with one of the following: an aromatase inhibitor (e.g., letrozole, anastrozole, exemestane) or fulvestrant. For men receiving an aromatase inhibitor: Will receive concomitant treatment for suppression of testicular steroidogenesis.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KORLYM

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Pregnancy.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KUVAN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

CONTINUATION OF THERAPY: Documentation of a reduction in blood phenylalanine levels since initiation of therapy.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Initial: 3 months. Reauthorization: 12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KYNAMRO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Repatha 420 mg, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LATUDA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LAZANDA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age 18 or greater

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Through the end of the Plan contract year.

#### **Other Criteria:**

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LEMTRADA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of TWO of the following, unless contraindicated or clinically significant adverse effects are experienced:  
Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, Copaxone, Glatopa, Extavia or Rebif.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LENVIMA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Medullary thyroid carcinoma.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RENAL CELL CARCINOMA: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Sutent, Nexavar, Votrient, Inlyta, Avastin in combination with Intron-A, Proleukin, Torisel AND Failure or clinically significant adverse effects to Opdivo or Cabometyx AND Must be used in combination with Afinitor.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LEUKINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Use Following Induction Chemotherapy in Acute Myelogenous Leukemia, Use in Mobilization and Following Transplantation of Autologous Peripheral Blood Progenitor Cells, Use in Myeloid Reconstitution After Autologous or Allogeneic Bone Marrow Transplantation: Failure of Neupogen, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LIDODERM

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Diabetic peripheral neuropathy. Cancer-related neuropathic pain.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LONSURF

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation that the patient does or does not have the KRAS wild type gene.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: 5-fluorouracil, capecitabine, oxaliplatin, irinotecan, Avastin, Cyramza, Zaltrap. If tumor expresses the KRAS wild type gene, failure of Erbitux or Vectibix, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LOTROXEX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Male patients.

#### **Required Medical Information:**

Female patient with irritable bowel symptoms persisting for at least 6 months.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LUNESTA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Rozerem, Silenor 6 mg/day or less, trazodone or temazepam.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

LYNPARZA CAPSULE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Mutations in the BRCA genes as detected by an FDA approved test.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LYNPARZA TABLET

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Breast cancer and non-maintenance treatment of ovarian, fallopian tube or primary peritoneal cancer: Mutations in the BRCA genes as detected by an FDA approved test. Breast Cancer: Documentation of human epidermal growth factor receptor 2 (HER2)-negative disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Maintenance treatment for ovarian, fallopian tube or primary peritoneal cancer: Completed two or more platinum-based chemotherapy regimens and is in a complete or partial response.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MAVYRET

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Treatment-experienced patients with both NS3/4A protease inhibitor and NS5A inhibitor.

#### **Required Medical Information:**

If cirrhosis is present, confirmation of Child-Pugh A status. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSa available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

8 to 16 weeks based on genotype, cirrhosis status, prior treatment regimen.

#### **Other Criteria:**

If member has been previously treated with an HCV regimen containing NS5A inhibitor or an NS3/4A protease inhibitor, but not both, member has genotype 1.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEGACE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Cachexia associated with cystic fibrosis.  
Cachexia associated with cancer.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

BREAST CANCER AND ENDOMETRIAL CANCER: Megestrol acetate is being used for palliative treatment.

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

ANOREXIA AND CACHEXIA ASSOCIATED WITH AIDS: Failure of dronabinol and oxandrolone, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEGACE ES

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Cachexia associated with cystic fibrosis.  
Cachexia associated with cancer.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

BREAST CANCER AND ENDOMETRIAL CANCER: Megestrol acetate is being used for palliative treatment.

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

ANOREXIA AND CACHEXIA ASSOCIATED WITH AIDS: Failure of dronabinol and oxandrolone, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEKINIST

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

MELANOMA: Positive for BRAF V600E or V600K mutation as detected by an FDA-approved test. NON-SMALL CELL LUNG CANCER: Positive for BRAF V600E mutation as detected by an FDA-approved test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

NON-SMALL CELL LUNG CANCER: Prescribed in combination with Tafenlar.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEPERIDINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Pain: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: codeine, hydromorphone, morphine, oxymorphone, hydrocodone/acetaminophen or oxycodone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEPROBAMATE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: venlafaxine, buspirone, duloxetine or escitalopram.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

METAXALONE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

METHAMPHETAMINE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Treatment of obesity.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

METHOCARBAMOL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

METHOTREXATE INJ

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of generic methotrexate injection, unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

METHYLDOPA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amlodipine/benazepril, benazepril, benazepril/hydrochlorothiazide, captopril, captopril/hydrochlorothiazide, fosinopril, fosinopril/hydrochlorothiazide, lisinopril, lisinopril/hydrochlorothiazide, quinapril, quinapril/hydrochlorothiazide, losartan, losartan/hydrochlorothiazide, valsartan, valsartan/hydrochlorothiazide, irbesartan, irbesartan/hydrochlorothiazide, candesartan, candesartan/hydrochlorothiazide, carvedilol, labetalol, acebutolol, atenolol, bisoprolol, bisoprolol/hydrochlorothiazide, timolol, nadolol, propranolol, metoprolol, metoprolol/hydrochlorothiazide, pindolol, nifedipine SR, amlodipine, nicardipine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

MIRCERA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Procrit (epoetin alfa), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MIRVASO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Erythema of rosacea with papules or pustules: Failure of topical metronidazole, oral doxycycline or Finacea, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MOZOBIL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of patient's current weight and absolute neutrophil count (ANC) dated within 30 days prior to the request.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Documented failure to reach and/or maintain a target absolute neutrophil count (ANC) with an adequate trial of Neupogen alone. Must be administered in combination with a granulocyte-colony stimulating factor (G-CSF) (i.e., filgrastim, filgrastim-sndz, or tbo-filgrastim).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NAMENDA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Vascular dementia.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 59 years and younger. Prior authorization is not required for patients 60 years and older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NATPARA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NERLYNX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months total duration of therapy.

#### **Other Criteria:**

Documentation of previous treatment with Herceptin as adjuvant therapy.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NEULASTA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Mobilization of peripheral-blood progenitor cells prior to autologous transplantation.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NEUPOGEN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Myelodysplastic syndrome. Neutropenia in patients with HIV/AIDS.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NINLARO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one prior therapy (e.g., Velcade, cyclophosphamide, doxorubicin, Revlimid, Thalomid, Alkeran), unless contraindicated or clinically significant adverse effects are experienced. Ninlaro must be used in combination with dexamethasone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NITROFURANTOIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Urinary tract infectious disease, Acute treatment: Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: sulfamethoxazole/trimethoprim or ciprofloxacin. Urinary tract infectious disease, Prophylaxis: Patient is continuing on this medication without adverse effects.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NORTHERA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NUCALA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Blood eosinophil count of greater than or equal to 150 cells/mcL within the past 3 months.

#### **Age Restrictions:**

ASTHMA: 12 years of age or older.

#### **Prescriber Restrictions:**

ASTHMA: Prescribed by or in consultation with an allergist, pulmonologist, or immunologist. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: Prescribed by or in consultation with a pulmonologist, immunologist, rheumatologist, or nephrologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

ASTHMA: Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: Failure of ONE glucocorticoid, unless contraindicated or clinically significant adverse events are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NUEDEXTA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NUPLAZID

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NUVIGIL

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OCALIVA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Must be used in combination with ursodeoxycholic acid unless patient is intolerant to ursodeoxycholic acid.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

OCREVUS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Relapsing Forms Of Multiple Sclerosis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, Copaxone, Glatopa, Extavia or Rebif.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ODOMZO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OFEV

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OPSUMIT

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ORALAIR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Severe, unstable or uncontrolled asthma. History of any severe allergic reaction to sublingual allergen immunotherapy.

#### **Required Medical Information:**

Positive skin test or in vitro testing for pollen-specific IgE antibodies for Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an allergist or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure to 2 of the following, unless contraindicated or clinically significant adverse effects are experienced: antihistamines, leukotriene modifiers or nasal steroids.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ORENITRAM

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ORKAMBI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Presence of homozygous F508del mutation in an FDA-cleared cystic fibrosis mutation test.

#### **Age Restrictions:**

2 years of age or older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ORPHENADRINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PENTAZOCINE/NALOXONE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: codeine, hydromorphone, morphine, oxycodone, hydrocodone/acetaminophen or oxycodone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PHENOBARBITAL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Partial seizures: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: carbamazepine, phenytoin, topiramate, tiagabine, levetiracetam, gabapentin, lamotrigine, oxcarbazepine, primidone or divalproex. Generalized seizures: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: carbamazepine, phenytoin, topiramate, levetiracetam, primidone or lamotrigine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PRALUENT

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Heterozygous Familial Hypercholesterolemia : Documentation (e.g., medical records, chart notes, laboratory values) of LDL level suggestive of a diagnosis of heterozygous familial hypercholesterolemia (e.g., Adults: LDL greater than 190 mg/dL). Hypercholesterolemia: Documentation of an LDL of 100 mg/dL or greater AND documented history of clinical atherosclerotic cardiovascular disease defined as one of the following: Acute coronary syndromes, Myocardial Infarction, Stable or unstable angina, Coronary or other arterial revascularization (e.g., percutaneous coronary intervention or coronary artery bypass graft surgery), Stroke, Peripheral artery disease presumed to be of atherosclerotic origin, Transient ischemic attack (TIA), Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging), Carotid artery occlusion greater than 50% without symptoms, Renal artery stenosis or renal artery stent procedure. CONTINUATION OF THERAPY: Documentation of LDL reduction while on Praluent therapy AND, if tolerated, confirmation of continued statin therapy at the maximally tolerated dose.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Failure of two of the following at maximally tolerated doses, unless contraindicated or clinically significant adverse effects are experienced: atorvastatin, rosuvastatin, simvastatin, ezetimibe/simvastatin, pitavastatin, pravastatin, fluvastatin, or lovastatin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PREVYMIS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Member is receiving pimozide or ergot alkaloids. Member is receiving cyclosporine co-administered with pitavastatin or simvastatin.

#### **Required Medical Information:**

Intravenous (IV) Prevymis: Medical justification why the member cannot use oral therapy.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncology, hematology, infectious disease, or transplant specialist.

#### **Coverage Duration:**

Through day 100 post-transplantation.

#### **Other Criteria:**

Failure of generic valacyclovir or generic ganciclovir, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PROCARDIA CAPSULES

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

CHRONIC STABLE ANGINA: Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: nifedipine SR, amlodipine or nicardipine. VASOSPASTIC ANGINA: Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: nifedipine SR or amlodipine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PROLIA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Hypocalcemia (unless corrected prior to initiating therapy).

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For men with non-metastatic prostate cancer: Receiving or has received androgen deprivation therapy [i.e., leuprolide (Lupron), bicalutamide (Casodex) or Nilandron]. For women with breast cancer: Receiving or has received adjuvant aromatase inhibitor therapy [i.e., anastrozole (Arimidex), exemestane (Aromasin) or letrozole (Femara)].

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PROMACTA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Thrombocytopenia in Chronic Hepatitis C: Documentation of current or planned interferon-based treatment of chronic hepatitis C.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Chronic Immune (Idiopathic) Thrombocytopenia: Failure of a corticosteroid (e.g., prednisone, methylprednisolone, or dexamethasone), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PROTOPIC

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Tacrolimus 0.1%: 16 years and older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two medium to high potency topical corticosteroids (e.g., amcinonide, fluticasone propionate, triamcinolone acetonide, betamethasone valerate, fluocinolone acetonide, hydrocortisone butyrate, mometasone furoate, desoximetasone, fluocinonide or betamethasone dipropionate), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

PROVIGIL

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Multiple sclerosis-related fatigue.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PURIXAN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Lymphoblastic lymphoma.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Member has a documented swallowing disorder or an inability to swallow tablets or capsules.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of mercaptopurine tablets, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

QUALAQUIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Babesiosis. Plasmodium vivax malaria.

#### **Exclusion Criteria:**

For the treatment or prevention of nocturnal leg cramps.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Malaria: 7 days. Babesiosis: 7-10 days.

#### **Other Criteria:**

Plasmodium vivax malaria: Infection is chloroquine-resistant.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

RADICAVA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Forced vital capacity greater than or equal to 80%, disease duration of less than or equal to 2 years, functionally retains most activities of daily living (defined as a baseline revised ALS Functional Rating Scale (ALSFRS-R) score with greater than or equal to 2 points in each of the 12 items, meets diagnostic criteria of definite or probable amyotrophic lateral sclerosis (ALS) based on El Escorial revised criteria. CONTINUATION OF THERAPY: Member continues to retain most activities of daily living, forced vital capacity greater than or equal to 80%, and ALSFRS-R score with greater than or equal to 2 points in each of the 12 items.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Prescribed in combination with riluzole unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

RANEXA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients on strong CYP3A inhibitors (e.g., ketoconazole, HIV protease inhibitors, clarithromycin) or CYP3A inducers (e.g., rifampin, phenobarbital).

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

RAYALDEE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Patient has stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D level less than 30 ng/mL.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

RELISTOR

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Amitiza and Movantik, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

REMICADE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Wegener's Granulomatosis.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Psoriatic Arthritis/Plaque Psoriasis: Prescribed by or in consultation with a rheumatologist or dermatologist.

Crohn's Disease/Ulcerative Colitis: Prescribed by or in consultation with a gastrointestinal (GI) specialist.

Rheumatoid Arthritis/Ankylosing Spondylitis: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Rheumatoid Arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

Plaque Psoriasis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

REPATHA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Heterozygous or Homozygous Familial Hypercholesterolemia : Documentation (e.g., medical records, chart notes, laboratory values) of LDL level suggestive of a diagnosis of familial hypercholesterolemia (e.g., Adults: LDL greater than 190 mg/dL). Hypercholesterolemia: Documentation of an LDL of 100 mg/dL or greater AND documented history of clinical atherosclerotic cardiovascular disease defined as one of the following: Acute coronary syndromes, Myocardial Infarction, Stable or unstable angina, Coronary or other arterial revascularization (e.g., percutaneous coronary intervention or coronary artery bypass graft surgery), Stroke, Peripheral artery disease presumed to be of atherosclerotic origin, Transient ischemic attack (TIA), Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging), Carotid artery occlusion greater than 50% without symptoms, Renal artery stenosis or renal artery stent procedure. CONTINUATION OF THERAPY: Documentation of LDL reduction while on Repatha therapy AND, if tolerated, confirmation of continued statin therapy at the maximally tolerated dose.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Failure of two of the following at maximally tolerated doses, unless contraindicated or clinically significant adverse effects are experienced: atorvastatin, rosuvastatin, simvastatin, ezetimibe/simvastatin, pitavastatin, pravastatin, fluvastatin, or lovastatin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

RESTASIS

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of one ophthalmic corticosteroid unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

REVATIO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Members on concomitant nitrates (e.g., Nitrodur, Nitrobid, Nitrostat, Isordil, Ismo). Members on concomitant guanylate cyclase stimulator, such as riociguat (Adempas).

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

REVLIMID

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Members who are pregnant.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

REXULTI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of aripiprazole and one of the following generic atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine, ziprasidone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

RITUXAN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Mantle Cell Lymphoma. Waldenstrom macroglobulinemia.

#### **Exclusion Criteria:**

Current or prior hepatitis B virus infection. Rheumatoid arthritis, Granulomatosis with polyangiitis, Microscopic polyangiitis: Concurrent use with biologic agents and DMARDs other than methotrexate.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia, Mantle cell lymphoma, Waldenstrom macroglobulinemia: Prescribed by or in consultation with an oncologist or hematologist. Rheumatoid arthritis, Granulomatosis with polyangiitis, Microscopic polyangiitis: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Rheumatoid Arthritis: Prescribed in combination with methotrexate, unless contraindicated or clinically significant adverse effects were experienced with prior methotrexate therapy AND Failure of Enbrel or Humira, unless contraindicated or clinically significant adverse effects are experienced. Granulomatosis with polyangiitis, Microscopic polyangiitis: Prescribed in combination with a glucocorticoid (e.g. prednisone, prednisolone, dexamethasone).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

RUBRACA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-MAINTENANCE TREATMENT: Mutations in the BRCA genes as detected by an FDA approved test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

MAINTENANCE TREATMENT: Completed two or more platinum-based chemotherapy regimens and is in a complete or partial response.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

RYDAPT

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Acute Myeloid Leukemia: Positive for the FLT3 mutation as detected by an FDA-approved test (e.g., LeukoStrat CDx FLT3 Mutation Assay).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Acute Myeloid Leukemia: Prescribed by or in consultation with an oncologist or hematologist. Advanced Systemic Mastocytosis: Prescribed by or in consultation with an oncologist, allergist, or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Acute Myeloid Leukemia: for induction therapy, prescribed in combination with cytarabine and daunorubicin OR for consolidation therapy, prescribed in combination with cytarabine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SAVELLA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Depression.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Fibromyalgia: Failure of duloxetine or Lyrica, unless contraindicated or clinically significant adverse effects are experienced. Depression: Failure of ONE of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine, or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SEROQUEL XR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Schizophrenia: Failure of two of the following generic atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine immediate release, ziprasidone, aripiprazole.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SILIQ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist or dermatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SIMPONI(auto-injector, prefilled syringe)

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist. ULCERATIVE COLITIS: Prescribed by or in consultation with a gastrointestinal (GI) specialist. RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PSORIATIC ARTHRITIS: Failure of methotrexate, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SIMPONI ARIA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist.  
RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PSORIATIC ARTHRITIS: Failure of methotrexate, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SOMA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SOMAVERT

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Inadequate response to surgery or radiation therapy, unless surgery or radiation therapy is not appropriate for the patient.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SONATA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Rozerem, Silenor 6 mg/day or less, trazodone or temazepam.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SOVALDI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. For the treatment of hepatitis C virus genotypes 5 and 6. Treatment of HCV genotype 2 or 3 in liver transplant recipients.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

Criteria will be applied consistent with current AASLD-IDSAs guidance.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Mavyret, Harvoni, Epclusa, Vosevi, and Zepatier for applicable genotypes.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SPRITAM

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Medical justification must be provided why patient cannot take generic levetiracetam tablets or liquid.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SPRYCEL

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Documentation that the member has Philadelphia chromosome positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist. GASTROINTESTINAL STROMAL TUMOR: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

GASTROINTESTINAL STROMAL TUMOR: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: imatinib, Sutent or Stivarga.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

STIVARGA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

STRENSIQ

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SUBSYS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age 18 or greater.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Through the end of the Plan contract year.

#### **Other Criteria:**

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SURMONTIL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Irritable bowel syndrome.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Depression: Failure of one of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine, or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SYMDEKO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Presence of homozygous F508del mutation or at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor.

#### **Age Restrictions:**

Age greater than or equal to 12 years.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SYMLINPEN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Previous use of mealtime insulin therapy or an insulin pump.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TAGRISSO

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Disease is positive for any of the following, as detected by an FDA-approved test: exon 19 deletions, exon 21 L858R mutations, or T790M mutation with progression on or after an EGFR TKI therapy (e.g., Tarceva, Iressa, or Gilotrif).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TARCEVA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Documentation of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

PANCREATIC CANCER: Prescribed in combination with gemcitabine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TASIGNA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Members with hypokalemia, hypomagnesemia, or long QT syndrome.

#### **Required Medical Information:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Documentation that the member has Philadelphia chromosome positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist. GASTROINTESTINAL STROMAL TUMOR: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

GASTROINTESTINAL STROMAL TUMOR: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: imatinib, Sutent or Stivarga.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TECENTRIQ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of platinum-containing chemotherapy (e.g., cisplatin or carboplatin), OR the patient is not eligible for cisplatin-containing chemotherapy. Non-small cell lung cancer: If a known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberration exists, then for ALK+ disease: prior trial of Xalkori, Alecensa, or Zykadia OR for EGFR+ disease: prior trial of Tarceva, Gilotrif or Iressa.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

TECFIDERA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

TENEX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amlodipine/benazepril, benazepril, benazepril/hydrochlorothiazide, captopril, captopril/hydrochlorothiazide, fosinopril, fosinopril/hydrochlorothiazide, lisinopril, lisinopril/hydrochlorothiazide, quinapril, quinapril/hydrochlorothiazide, losartan, losartan/hydrochlorothiazide, valsartan, valsartan/hydrochlorothiazide, irbesartan, irbesartan/hydrochlorothiazide, candesartan, candesartan/hydrochlorothiazide, carvedilol, labetalol, acebutolol, atenolol, bisoprolol, bisoprolol/hydrochlorothiazide, timolol, nadolol, propranolol, metoprolol, metoprolol/hydrochlorothiazide, pindolol, nifedipine SR, amlodipine, nicardipine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

TETRABENAZINE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TREMFYA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist or dermatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine, or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TRIHEXYPHENIDYL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Parkinsons disease/Parkinsonism: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amantadine, levodopa/carbidopa, entacapone, pramipexole, ropinirole, selegiline.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TYMLOS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Total duration of therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) has not exceeded 2 years.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of a bisphosphonate (e.g., alendronate) unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TYSABRI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients who have or have had progressive multifocal leukoencephalopathy.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

MULTIPLE SCLEROSIS: Prescribed by or in consultation with a neurologist. CROHN'S DISEASE: Prescribed by or in consultation with a GI specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RELAPSING FORMS OF MULTIPLE SCLEROSIS: Failure or clinically significant adverse effects to one of the following: Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, Copaxone, Glatopa, Extavia or Rebif.  
CROHN'S DISEASE: Failure or clinically significant adverse effects to Humira or Remicade.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ULTRAVATE LOTION

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of generic halobetasol propionate and generic clobetasol propionate, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

UPTRAVI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VALCHLOR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following skin-directed therapies, unless contraindicated or clinically significant adverse effects are experienced: topical corticosteroids (e.g., clobetasol, triamcinolone), Targretin gel, Tazorac, or imiquimod.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VANCOGIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, infectious disease specialist or hospitalist.

#### **Coverage Duration:**

C. Diff diarrhea: 14 days. Staph enterocolitis: 10 days. Recurrent C. Diff: 10 weeks.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VENCLEXTA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Chronic Lymphocytic Leukemia without 17p deletion.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of CLL with or without 17p deletion.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of at least one previous therapy (e.g., Imbruvica, Campath, high-dose methylprednisolone with Rituxan), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VERSACLOZ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Psychotic disorder associated with Parkinson's disease.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of clozapine (Clozaril) or FazaClo, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VERZENIO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VIBERZI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of loperamide unless contraindicated or clinically significant adverse effects are experienced AND For members 64 years and younger, failure of diphenoxylate-atropine (Lomotil) or dicyclomine, unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### Prior Authorization Group Description:

VIMOVO

#### Covered Uses:

All FDA-approved indications not otherwise excluded from Part D.

#### Exclusion Criteria:

#### Required Medical Information:

#### Age Restrictions:

#### Prescriber Restrictions:

#### Coverage Duration:

12 months.

#### Other Criteria:

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: pantoprazole, lansoprazole or omeprazole AND For osteoarthritis or rheumatoid arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: ibuprofen, diclofenac sodium or potassium, etodolac, fenoprofen, ketoprofen, meloxicam, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin OR For ankylosing spondylitis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: diclofenac sodium, naproxen or sulindac OR For juvenile idiopathic arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: etodolac, ibuprofen, meloxicam, naproxen, oxaprozin, tolmetin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VINBLASTINE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation that vinblastine is being used as palliative therapy.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VINCRIStINE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VOSEVI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

If cirrhosis is present, confirmation of Child-Pugh A status. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 weeks.

#### **Other Criteria:**

If HCV genotype 1, 2, 3, 4, 5 or 6, member has previously been treated with an HCV regimen containing one of the following NS5A inhibitors: daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir. Alternatively, if HCV genotype is 1a or 3, member has previously been treated with an HCV regimen containing sofosbuvir.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VOTRIENT

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

SOFT TISSUE SARCOMA: Member has received prior chemotherapy (e.g., regimens containing doxorubicin or epirubicin).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VRAYLAR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of TWO of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: aripiprazole, ziprasidone, quetiapine, olanzapine, risperidone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VYTORIN 10/80 MG

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Member has been taking ezetimibe 10 mg/simvastatin 80 mg for 12 months or longer.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XALKORI

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Documentation of ALK, ROS1, or MET positive disease.  
INFLAMMATORY MYOFIBROBLASTIC TUMOR, ANAPLASTIC LARGE CELL LYMPHOMA:  
Documentation of ALK-positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XATMEP

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

##### **Age Restrictions:**

Less than 18 years of age.

##### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist (for acute lymphoblastic leukemia) or rheumatologist (for polyarticular juvenile idiopathic arthritis).

##### **Coverage Duration:**

12 months.

##### **Other Criteria:**

Medical justification as to why member cannot use methotrexate tablets.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XELJANZ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

RHEUMATOID ARTHRITIS: Prescribed by or in consultation with a rheumatologist. PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PSORIATIC ARTHRITIS: Failure of methotrexate, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

XEOMIN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XERMELO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Prescribed in combination with a somatostatin analog (e.g., octreotide, lanreotide) unless contraindicated or clinically significant adverse effects are experienced.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure to a trial of a somatostatin analog (e.g., octreotide, lanreotide) unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XOLAIR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

ASTHMA: Positive skin test or in vitro reactivity to a perennial aeroallergen AND confirmed total serum IgE level greater than 30 IU/ml.

#### **Age Restrictions:**

ASTHMA: 6 years of age or older. CHRONIC IDIOPATHIC URTICARIA: 12 years of age or older.

#### **Prescriber Restrictions:**

ASTHMA: Prescribed by or in consultation with a pulmonologist, immunologist, or allergist. CHRONIC IDIOPATHIC URTICARIA: Prescribed by or in consultation with an allergist, dermatologist, or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

ASTHMA: Failure of one inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced.  
CHRONIC IDIOPATHIC URTICARIA: Failure of one H1 Antihistamine (e.g., levocetirizine or desloratadine), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XTANDI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

YERVOY

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Small cell lung cancer.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

SMALL CELL LUNG CANCER: Failure of a platinum-containing regimen (e.g., cisplatin, carboplatin containing regimen). SMALL CELL LUNG CANCER, RENAL CELL CARCINOMA: Prescribed in combination with Opdivo.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZALTRAP

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Colorectal cancer is resistant or has progressed following an oxaliplatin-containing regimen AND Zaltrap will be used in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZARXIO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Myelodysplastic syndrome. Neutropenia in patients with HIV/AIDS. Hematopoietic syndrome of acute radiation syndrome.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZEJULA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Completed two or more platinum-based chemotherapy regimens and is in a complete or partial response.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZELBORAF

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients with wild-type BRAF disease.

#### **Required Medical Information:**

MELANOMA, NON-SMALL CELL LUNG CANCER, ERDHEIM-CHESTER DISEASE: Positive for the BRAF V600E mutation detected by an FDA-approved test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

NON-SMALL CELL LUNG CANCER: Failure of Tafinlar or Mekinist, unless contraindicated or clinically significant adverse effects are experienced. THYROID CARCINOMA: Failure of Lenvima or Nexavar, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZEPATIER

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

If cirrhosis is present, confirmation of Child-Pugh A status. For genotype 1a, documentation of presence or absence of NS5A resistance-associated polymorphisms. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSA available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 to 16 wks based on genotype,presence of NS5A resistance-associated polymorphisms,prior treatment.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZINPLAVA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of positive Clostridium difficile test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

4 weeks.

#### **Other Criteria:**

Will receive or is currently receiving antibacterial drug treatment for Clostridium difficile infection (e.g., metronidazole, vancomycin, fidaxomicin) concomitantly with Zinplava. Has received appropriate treatment for past CDI recurrences, including a pulsed vancomycin regimen.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZOLPIDEM

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Rozerem, Silenor 6 mg/day or less, trazodone or temazepam.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ZYDELIG

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a hematologist or oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZYKADIA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL Cell LUNG CANCER: Documentation of ALK or ROS1 positive disease. INFLAMMATORY MYOFIBROBLASTIC TUMOR: Documentation of ALK-positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZYTIGA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with prednisone. Member has previously had bilateral orchiectomy, failed androgen deprivation therapy (ADT) or will use ADT concurrently with Zytiga.

ABSTRAL . . . . .	1	CRINONE . . . . .	48
ACTEMRA SC . . . . .	2	CROFELEMER . . . . .	49
ACTIQ . . . . .	3	CYCLOBENZAPRINE HCL . . . . .	50
ACYCLOVIR . . . . .	4	CYTARABINE . . . . .	51
ADCIRCA . . . . .	5	DAKLINZA . . . . .	52
ADEMPAS . . . . .	6	DIPYRIDAMOLE . . . . .	53
AFINITOR . . . . .	7	DISOPYRAMIDE . . . . .	54
ALECENSA . . . . .	8	DOXEPIN . . . . .	55
ALUNBRIG . . . . .	9	ELIDEL . . . . .	56
AMITRIPTYLINE . . . . .	10	EMEND 40 MG . . . . .	57
AMITRIPTYLINE/CHLORDIAZEPOXIDE . . . . .	11	EMFLAZA . . . . .	58
AMITRIPTYLINE/PERPHENAZINE . . . . .	12	ENBREL . . . . .	59
AMPHOTERICIN B . . . . .	13	ENDARI . . . . .	60
AMPYRA . . . . .	14	ENTRESTO . . . . .	61
ANTI-HISTAMINES . . . . .	15	ENTYVIO . . . . .	62
ANTI-HISTAMINE COMBINATIONS . . . . .	16	EPCLUSA . . . . .	63
ARANESP . . . . .	17	EPOETIN . . . . .	64
AUBAGIO . . . . .	18	ERGOLOID MESYLATES . . . . .	65
AUSTEDO . . . . .	19	ERLEADA . . . . .	66
AVASTIN . . . . .	20	ESBRIET . . . . .	67
BAXDELA . . . . .	21	ESTROGENS(Fyavolv , Mimvey Lo , Minivelle , Femhrt , Vivelle-Dot , Menostar , Premphase , Premarin , Lopreeza , Alora , Amabelz , Prempro , Mimvey , Climara Pro , Combipatch , Angeliq , Elestrin , Climara , Divigel , Duavee , Activella , Estrace , Evamist , estropipate) . . . . .	68
BELEODAQ . . . . .	22	EVZIO . . . . .	69
BELSOMRA . . . . .	23	EXONDYS 51 . . . . .	70
BENLYSTA . . . . .	24	EYLEA . . . . .	71
BENZTROPINE . . . . .	25	FARYDAK . . . . .	72
BLEOMYCIN . . . . .	26	FASENRA . . . . .	73
BOSULIF . . . . .	27	FENTORA . . . . .	74
BOTOX . . . . .	28	FERRIPROX . . . . .	75
BRIVIACT . . . . .	29	FIORICET WITH CODEINE . . . . .	76
BUTABARBITAL . . . . .	30	FIORINAL WITH CODEINE . . . . .	77
C1 ESTERASE INHIBITOR . . . . .	31	FIRAZYR . . . . .	78
CABOMETYX . . . . .	32	FLECTOR . . . . .	79
CALQUENCE . . . . .	33	FLUOROURACIL . . . . .	80
CAPRELSA . . . . .	34	FORTEO . . . . .	81
CARISOPRODOL/ASPIRIN . . . . .	35	GANCICLOVIR . . . . .	82
CARISOPRODOL/ASPIRIN/CODEINE . . . . .	36	GATTEX . . . . .	83
CAYSTON . . . . .	37	GILENYA . . . . .	84
CERDELGA . . . . .	38	GILOTRIF . . . . .	85
CEREZYME . . . . .	39	GLATIRAMER . . . . .	86
CHLORPROPAMIDE . . . . .	40	GLYBURIDE . . . . .	87
CHLORZOXAZONE . . . . .	41	GLYBURIDE/METFORMIN . . . . .	88
CHORIONIC GONADOTROPIN . . . . .	42	GOCOVRI . . . . .	89
CINQAIR . . . . .	43	GRANIX . . . . .	90
CLADRIBINE . . . . .	44	GRASTEK . . . . .	91
CLOMIPRAMINE . . . . .	45		
COMETRIQ . . . . .	46		
COTELLIC . . . . .	47		

HARVONI . . . . .	92	LUNESTA . . . . .	139
HERCEPTIN . . . . .	93	LYNPARZA CAPSULE . . . . .	140
HETLIOZ . . . . .	94	LYNPARZA TABLET . . . . .	141
HUMAN GROWTH HORMONE . . . . .	95	MAVYRET . . . . .	142
HUMIRA . . . . .	96	MEGACE . . . . .	143
HYDROCODONE . . . . .	97	MEGACE ES . . . . .	144
HYDROXYZINE HCL . . . . .	98	MEKINIST . . . . .	145
HYDROXYZINE HCL INJECTION . . . . .	99	MEPERIDINE . . . . .	146
HYDROXYZINE PAMOATE . . . . .	100	MEPROBAMATE . . . . .	147
ICLUSIG . . . . .	101	METAXALONE . . . . .	148
IDHIFA . . . . .	102	METHAMPHETAMINE . . . . .	149
ILARIS . . . . .	103	METHOCARBAMOL . . . . .	150
IMATINIB . . . . .	104	METHOTREXATE INJ . . . . .	151
IMBRUVICA . . . . .	105	METHYLDOPA . . . . .	152
IMIPRAMINE . . . . .	106	MIRCERA . . . . .	153
INDOMETHACIN . . . . .	107	MIRVASO . . . . .	154
INFLECTRA . . . . .	108	MOZOBIL . . . . .	155
INGREZZA . . . . .	109	NAMENDA . . . . .	156
INLYTA . . . . .	110	NATPARA . . . . .	157
INTERFERON BETA-1A . . . . .	111	NERLYNX . . . . .	158
INTERFERON BETA-1B . . . . .	112	NEULASTA . . . . .	159
INTERMEZZO 1.75 MG . . . . .	113	NEUPOGEN . . . . .	160
INTERMEZZO 3.5 MG . . . . .	114	NINLARO . . . . .	161
INTUNIV . . . . .	115	NITROFURANTOIN . . . . .	162
JAKAFI . . . . .	116	NORTHERA . . . . .	163
JUBLIA . . . . .	117	NUCALA . . . . .	164
JUXTAPID . . . . .	118	NUEDEXTA . . . . .	165
KADCYLA . . . . .	119	NUPLAZID . . . . .	166
KADIAN . . . . .	120	NUVIGIL . . . . .	167
KALYDECO . . . . .	121	OICALIVA . . . . .	168
KERYDIN . . . . .	122	OCREVUS . . . . .	169
KETOROLAC TROMETHAMINE . . . . .	123	ODOMZO . . . . .	170
KEVEYIS . . . . .	124	OFEV . . . . .	171
KEVZARA . . . . .	125	OPSUMIT . . . . .	172
KEYTRUDA . . . . .	126	ORALAIR . . . . .	173
KISQALI(Kisqali , Kisqali Femara Co-Pack ) . . . . .	127	ORENITRAM . . . . .	174
KORLYM . . . . .	128	ORKAMBI . . . . .	175
KUVAN . . . . .	129	ORPHENADRINE . . . . .	176
KYNAMRO . . . . .	130	PENTAZOCINE/NALOXONE . . . . .	177
LATUDA . . . . .	131	PHENOBARBITAL . . . . .	178
LAZANDA . . . . .	132	PRALUENT . . . . .	179
LEMTRADA . . . . .	133	PREVYMIS . . . . .	180
LENVIMA . . . . .	134	PROCARDIA CAPSULES . . . . .	181
LEUKINE . . . . .	135	PROLIA . . . . .	182
LIDODERM . . . . .	136	PROMACTA . . . . .	183
LONSURF . . . . .	137	PROTOPIC . . . . .	184
LOTRONEX . . . . .	138	PROVIGIL . . . . .	185

PURIXAN . . . . .	186	VENCLEXTA . . . . .	233
QUALAQUIN . . . . .	187	VERSACLOZ . . . . .	234
RADICAVA . . . . .	188	VERZENIO . . . . .	235
RANEXA . . . . .	189	VIBERZI . . . . .	236
RAYALDEE . . . . .	190	VIMOVO . . . . .	237
RELISTOR . . . . .	191	VINBLASTINE . . . . .	238
REMICADE . . . . .	192	VINCRISTINE . . . . .	239
REPATHA . . . . .	193	VOSEVI . . . . .	240
RESTASIS . . . . .	194	VOTRIENT . . . . .	241
REVATIO . . . . .	195	VRAYLAR . . . . .	242
REVLIMID . . . . .	196	VYTORIN 10/80 MG . . . . .	243
REXULTI . . . . .	197	XALKORI . . . . .	244
RITUXAN . . . . .	198	XATMEP . . . . .	245
RUBRACA . . . . .	199	XELJANZ . . . . .	246
RYDAPT . . . . .	200	XEOMIN . . . . .	247
SAVELLA . . . . .	201	XERMELO . . . . .	248
SEROQUEL XR . . . . .	202	XOLAIR . . . . .	249
SILIQ . . . . .	203	XTANDI . . . . .	250
SIMPONI(auto-injector, prefilled syringe) . . . . .	204	YERVOY . . . . .	251
SIMPONI ARIA . . . . .	205	ZALTRAP . . . . .	252
SOMA . . . . .	206	ZARXIO . . . . .	253
SOMAVERT . . . . .	207	ZEJULA . . . . .	254
SONATA . . . . .	208	ZELBORAF . . . . .	255
SOVALDI . . . . .	209	ZEPATIER . . . . .	256
SPRITAM . . . . .	210	ZINPLAVA . . . . .	257
SPRYCEL . . . . .	211	ZOLPIDEM . . . . .	258
STIVARGA . . . . .	212	ZYDELIG . . . . .	259
STRENSIQ . . . . .	213	ZYKADIA . . . . .	260
SUBSYS . . . . .	214	ZYTIGA . . . . .	261
SURMONTIL . . . . .	215		
SYMDEKO . . . . .	216		
SYMLINPEN . . . . .	217		
TAGRISSE . . . . .	218		
TARCEVA . . . . .	219		
TASIGNA . . . . .	220		
TECENTRIQ . . . . .	221		
TECFIDERA . . . . .	222		
TENEX . . . . .	223		
TETRABENAZINE . . . . .	224		
TREMFYA . . . . .	225		
TRIHEXYPHENIDYL . . . . .	226		
TYMLOS . . . . .	227		
TYSABRI . . . . .	228		
ULTRAVATE LOTION . . . . .	229		
UPTRAVI . . . . .	230		
VALCHLOR . . . . .	231		
VANCOGIN . . . . .	232		